Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Thiamine Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.95 |
| ▸ | TKT | P29401 | 12/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiamine Ion SCHEMBL10074 | 0.99 | HSP90AA1 (0.98) | HSP90AA1TKTTDP1KDM4ELMNA | |
| Thiamine Ion SCHEMBL29572584 | 0.99 | HSP90AA1 (0.98) | HSP90AA1TKTTDP1KDM4ELMNA | |
| Thiamine Ion SCHEMBL29445547 | 0.99 | HSP90AA1 (0.98) | HSP90AA1TKTTDP1KDM4ELMNA | |
| Thiamine Ion SCHEMBL7090274 | 0.99 | HSP90AA1 (0.98) | HSP90AA1TKTTDP1KDM4ELMNA | |
| Thiamine Ion SCHEMBL5317564 | 0.98 | HSP90AA1 (0.95) | HSP90AA1TKTTDP1KDM4ELMNA | |
| Thiamine Ion SCHEMBL6687656 | 0.98 | HSP90AA1 (0.95) | HSP90AA1TKTTDP1KDM4ELMNA | |
| Thiamine Ion SCHEMBL7111895 | 0.98 | HSP90AA1 (0.95) | HSP90AA1TKTTDP1KDM4ELMNA | |
| Thiamine Ion SCHEMBL10636112 | 0.98 | HSP90AA1 (0.95) | HSP90AA1TKTTDP1KDM4ELMNA | |
| Thiamine Ion SCHEMBL9618672 | 0.98 | HSP90AA1 (0.95) | HSP90AA1TKTTDP1KDM4ELMNA | |
| Thiamine Ion SCHEMBL10636119 | 0.98 | HSP90AA1 (0.95) | HSP90AA1TKTTDP1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676451-A1 | COMPOSITION COMPRISING MEDIUM-CHAIN TRIGLYCERIDES, OMEGA-3 AND CHOLINE FOR USE IN A METHOD OF TREATMENT OF COGNITIVE DECLINE AND DEMENTIA | Global Pharmacies Partner S.R.L. in Forma Abbreviata G.P.P. S.R.L. (IT) | 2026-01-14 | — | — | EP | claimed |
| WO-2024184869-A1 | COMPOSITION COMPRISING MEDIUM-CHAIN TRIGLYCERIDES, OMEGA-3 AND CHOLINE FOR USE IN A METHOD OF TREATMENT OF COGNITIVE DECLINE AND DEMENTIA | GLOBAL PHARMACIES PARTNER S.R.L. IN FORMA ABBREVIATA G.P.P. S.R.L. (IT) | 2024-09-12 | — | — | WO | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260085292-A1 | MINIMAL ESSENTIAL MEDIA FOR THE CULTURE OF HUMAN INDUCED PLURIPOTENT STEM CELLS | UNIV NORTHWESTERN (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260061056-A1 | RINSE SOLUTION FOR A PHOTODYNAMIC DISINFECTION | MANA HEALTH TECHNOLOGIES GMBH (AT) | 2026-03-05 | — | — | US | disclosed |
| EP-4676451-A1 | COMPOSITION COMPRISING MEDIUM-CHAIN TRIGLYCERIDES, OMEGA-3 AND CHOLINE FOR USE IN A METHOD OF TREATMENT OF COGNITIVE DECLINE AND DEMENTIA | Global Pharmacies Partner S.R.L. in Forma Abbreviata G.P.P. S.R.L. (IT) | 2026-01-14 | — | — | EP | disclosed |
| US-20250387309-A1 | METHOD FOR THE TREATMENT OF KERATIN FIBRES COMPRISING A PRETREATMENT OR POST-TREATMENT STEP | OREAL (FR) | 2025-12-25 | — | — | US | disclosed |
| EP-4584365-A2 | MINIMAL ESSENTIAL MEDIA FOR THE CULTURE OF HUMAN INDUCED PLURIPOTENT STEM CELLS | Northwestern University (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-119639644-A | Pichia pastoris chemical composition limiting culture medium for producing recombinant protein | 福建师范大学 | 2025-03-18 | — | — | CN | disclosed |
| CN-119120323-A | Chemical composition limiting culture medium for escherichia coli fermentation culture and plasmid expression | 上海东富龙生物试剂有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240341328-A1 | FUNCTIONAL COMPONENT-CONTAINING BEVERAGE FILLED IN SPRAYING CONTAINER | SUNTORY HOLDINGS LIMITED (JP) | 2024-10-17 | — | — | US | disclosed |
| US-7452555-B2 | Cocrystallization | S.S.C.I., INC. (US) | 2008-11-18 | — | — | US | disclosed |
| CN-101268039-A | Novel carboxylic acid derivatives | DSM IP ASSETS BV (NL) | 2008-09-17 | — | — | CN | disclosed |
| WO-2008087010-A1 | USE OF NICOTINAMIDE FOR TREATMENT AND/OR PREVENTION OF ARTERIOSCLEROSIS | MEDICE ARZNEIMITTEL PUETTER GMBH & CO. KG (DE) | 2008-07-24 | — | — | WO | disclosed |
| EP-1926703-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES | DSM IP Assets B.V. (NL) | 2008-06-04 | — | — | EP | disclosed |
| US-20070287194-A1 | Screening For Solid Forms By Ultrasound Crystallization And Cocrystallization Using Ultrasound | S.S.C.I., INC | 2007-12-13 | — | — | US | disclosed |
| US-20070088508-A1 | Cocrystallization methods | APTUIT (WEST LAFAYETTE), LLC | 2007-04-19 | — | — | US | disclosed |
| WO-2007039059-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2007-04-12 | — | — | WO | disclosed |
| WO-2005123099-A2 | METHODS AND COMPOSITIONS FOR ACCELERATING ALCOHOL METABOLISM | ENZYMEDIX, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050271739-A1 | Methods and compositions for accelerating alcohol metabolism | ENZYMEDIX | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085292-A1 | MINIMAL ESSENTIAL MEDIA FOR THE CULTURE OF HUMAN INDUCED PLURIPOTENT STEM CELLS | SLC7A11, GLUL, KCNN2 | HSP90AA1 2823/4885TKT 1710/4885TDP1 4329/4885 |
| US-20250387309-A1 | METHOD FOR THE TREATMENT OF KERATIN FIBRES COMPRISING A PRETREATMENT OR POST-TREATMENT STEP | PROC, KRT18, VCL | HSP90AA1 936/4885TKT 1348/4885TDP1 4246/4885 |
| US-20260061056-A1 | RINSE SOLUTION FOR A PHOTODYNAMIC DISINFECTION | PRPS1, UROD, PDE6D | HSP90AA1 2555/4885TKT 967/4885TDP1 453/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | HSP90AA1 1524/4885TKT 1842/4885TDP1 3124/4885 |
| US-20050271739-A1 | Methods and compositions for accelerating alcohol metabolism | ADH1A, ADH1C, ADH5 | HSP90AA1 2426/4885TKT 81/4885TDP1 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.